Schering Corporation

Merck Sharp + Dohme Corp.

Other

Sydney O Ugwu

Peter M Ihnat

Vinay Radhakrishnan

Leonore Catherine Witchey-Lakshmanan

Lenore C Witchey-Lakshmanan

Imran Ahmad

Varda E Sandweiss

Jia-Ai Zhang

Lan Ma

Gopal Anyarambhatla

Varda Sandweiss

Disclosed are aqueous and lyophilized formulations containing SYN3 and methods of their use for treating bladder cancer.

SYN3 compositions and methods

In its several embodiments, this invention discloses a pharmaceutical formulation comprising at least one antineoplastic agent or a pharmaceutically acceptable salt thereof, and at least one dissolution enhancing agent sufficient to substantially dissolve said at least one antineoplastic agent in at least one aqueous diluent, wherein said dissolution enhancing agent is urea, L-histidine, L-threonine, L-asparagine, L-serine, L-glutamine or mixtures thereof; a lyophilized powder comprising said pharmaceutical formulation, and articles of manufacture thereof.

Processes of making and using pharmaceutical formulations of antineoplastic agents

The invention provides a formulation of one or more antineoplastic drugs encapsulated in liposomes including at least a lipid fraction in addition to the antineoplastic drug, wherein the composition is stable in an aqueous solution at room temperature.

Stable sterile filterable liposomal encapsulated taxane and other antineoplastic drugs

Processes of making pharmaceutical formulations of antineoplastic agents

Pharmaceutical formulations of antineoplastic agents

Pharmaceutical formulations of antineoplastic agents and processes of making and using the same

Growing community of inventors

Chicago, IL, United States of America

Sydney O Ugwu